PreDia® works by helping to reduce the presence of sugar in the blood while helping to save your insulin. While may products claim to do this, PreDia® achieves this in an all-new way using a new ingredient. PreDia’s main function revolves around Abscisic acid (ABA) contained in its Grape Seed extract ingredient.
Our unique and patent dosage of ABA reduces blood sugar levels after a meal independent of insulin. In other words, PreDia® helps reduce the glucose in the blood independent of insulin (where normally it is needed to reduce the blood sugar). By doing this, not only is insulin saved, but the pancreas no longer produces excess insulin, thus helping to stop insulin resistance one of the cornerstones of Type 2 Diabetes.
Studies have confirmed this by showing that the dose of ABA contained in PreDia® can replace the insulin action by stimulating the skeletal muscle glucose uptake. The ability of saving insulin secretion to control glycemia represents the most important function of PreDia®.*
Combatting prediabetes is as simple as changing your lifestyle. Reducing your intake of refined carbohydrates and sugars, eating more foods rich in protein, healthy fats and fiber, and becoming more active are great ways to boost insulin sensitivity and reduce blood sugar levels.
Abscisic acid (ABA) is a plant hormone that helps regulate the responses of plants to changing environmental conditions, such as weather, light, nutrient and water availability. For example, ABA has been shown to help plants adapt to changing climate conditions by controlling nutrient metabolism and protecting plant seeds. Unexpectedly, ABA has been also detected in mammals where it regulates immune cell activity. This prompted further exploration into the effects of ABA on humans.
Scientific evidence indicates that plasma ABA increases after a glucose load in healthy humans, similarly to insulin, which also increases after a glucose load to help manage blood sugar levels and convert them into energy. Further studies in animals and in humans have shown that ABA also exhibits regulatory functions in managing blood sugar levels and lipid metabolism. Such findings make ABA a new and attractive molecule for treating people who have prediabetes and metabolic syndrome.
The area under the curve of glycemia after a carbohydrate load
Insulin levels after an oral glucose load
Glycated hemoglobin over a 4-month high glucose diet
Body weight gain over a 4-month high glucose diet
Cholesterol and triglycerides levels over a 4-month high glucose diet.
Insulin-independent skeletal muscle glucose uptake
Skeletal muscle glycogen storage.
Panels A and B. Intake of ABA at 1 μg/Kg body weight (BW) lowers glycemia and insulinemia in rats subjected to an OGTT. Four groups of male Wistar rats were subjected to an oral glucose load (1 g glucose/Kg). The glucose solution was administered without (OGTT) or with an aqueous apricot extract (OGTT+extr) containing ABA at a dose of 1 μg/Kg, or with synthetic ABA at 1 μg/Kg (OGTT+ABA). The area-under-the-curve (AUC) values of glycemia (A) and insulinemia (B) over the 0–120 min time frame are shown; p values by unpaired two-tailed t-test compared to untreated animals.
Panels C, D, E. Synthetic ABA at 1 μg/Kg BW improves metabolic parameters in mice fed a high-glucose diet. Seven-week-old male CD1 mice (nine/group) were fed for 4 months a high-glucose diet containing 1 g/Kg BW glucose without (controls) or with ABA at 1 μg/Kg BW. At the end of the study, HbA1c (C), body weight (D) and fasting lipidemia (E), and were measured. Mean ± SD values are shown. p values by unpaired, two-tailed t-test.
Thanks to its patented ABA formulation, PreDia®, along with a balanced diet and exercise, is proven to reduce the glycemic profile after a meal and can provide optimal management of the glucose and lipid metabolism during a daily administration. Recently, a three-month open clinical study was performed with PreDia®. Participants in the study using PreDia® experienced lower Fasting glycemia, HbA1c, total cholesterol levels, and body weight & waist circumference. Additional studies confirm the efficacy of ABA in the glycemic and lipidemic control. By taking one tablet a day, PreDia® ensures that it can help reduce the typical markers associated with prediabetes and metabolic syndrome.
Pre- vs. post-treatment comparison of the metabolic parameters explored in “borderline subjects” treated for 75 days with PreDia®. Mean values of each parameter were calculated in “borderline subjects”. Percentage of reduction (% reduction) was calculated between the mean value at “end” and “start” for each parameter. Start = day 1 of the study; end = day 75 of the study. The cardiovascular risk was calculated for each subject as the ratio between total cholesterol and HDL. The p value (start vs. end) was calculated by one-tailed, paired T test. FBG: fasting blood glycemia; HbA1c: glycated hemoglobin A1c; TC: total cholesterol; BMI: body mass index; WC: waist circumference.
Mean ± SD values of the glycemia profiles obtained during a standardized carbohydrate-rich meal on the same subjects with (orange line) or without (blue line) the intake of PreDia® before the meal. Intake of the two meals occurred one week apart for each subject.P values by one-tail,paired T-test: *P=0.0007; **P=0.006; ***P=0.014
The dose of ABA contained in PreDia® improves glucose tolerance by increasing muscle glucose uptake and metabolism without increasing insulin release. Reduction of insulinemia in turn counteracts body weight gain and insulin resistance, which are hallmarks of prediabetes and the metabolic syndrome.
Still have questions? Call, or send us an email to learn more about how PreDia® can help.
*These Statements Have Not Been Evaluated By The Food & Drug Administration.This Product is Not Intended To Diagnose, Treat, Cure or Prevent Any Disease.
